Paper41547728
Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-naïve prostate cancer.
Tosun I and 4 others. BMC Urol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-naïve prostate cancer. Papers, record 41547728. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41547728
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-naïve prostate cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| B7-H1 Antigen | Major topic |
| Adenocarcinoma | Major topic |
| Humans | |
| Male | |
| Prognosis | |
| Retrospective Studies | |
| Aged | |
| Synaptophysin | |
| Middle Aged | |
| Cell Differentiation |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24705311 | Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. | Am J Surg Pathol | 2014 | https://conductscience.org/library/papers/24705311 | PubMed |
| 2 | 33339136 | Neuroendocrine and Aggressive-Variant Prostate Cancer. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33339136 | PubMed |
| 3 | 29985747 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29985747 | PubMed |
| 4 | 38808339 | Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors. | World J Clin Cases | 2024 | https://conductscience.org/library/papers/38808339 | PubMed |
| 5 | 25606573 | Neuroendocrine differentiation of prostate cancer: a review. | Am J Clin Exp Urol | 2014 | https://conductscience.org/library/papers/25606573 | PubMed |
| 6 | 28893901 | Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28893901 | PubMed |
| 7 | 34784097 | Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. | BJU Int | 2022 | https://conductscience.org/library/papers/34784097 | PubMed |
| 8 | 39380471 | The Immune Microenvironment in Prostate Cancer: A Comprehensive Review. | Oncology | 2025 | https://conductscience.org/library/papers/39380471 | PubMed |
| 9 | 29535806 | Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. | Oncotarget | 2018 | https://conductscience.org/library/papers/29535806 | PubMed |
| 10 | 38423221 | Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression. | Hum Pathol | 2024 | https://conductscience.org/library/papers/38423221 | PubMed |
| 11 | 40273724 | PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer. | Ann Diagn Pathol | 2025 | https://conductscience.org/library/papers/40273724 | PubMed |
| 12 | 39279246 | Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53. | Prostate | 2024 | https://conductscience.org/library/papers/39279246 | PubMed |
| 13 | 29297494 | Neuroendocrine tumors of the prostate. | Mod Pathol | 2018 | https://conductscience.org/library/papers/29297494 | PubMed |
| 14 | 28788048 | Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28788048 | PubMed |
| 15 | 32474391 | Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. | Crit Rev Oncol Hematol | 2020 | https://conductscience.org/library/papers/32474391 | PubMed |
| 16 | 32344931 | Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. | Cells | 2020 | https://conductscience.org/library/papers/32344931 | PubMed |
| 17 | 31547070 | Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31547070 | PubMed |
| 18 | 31061129 | Genomic correlates of clinical outcome in advanced prostate cancer. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/31061129 | PubMed |
| 19 | 22767265 | Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. | Virchows Arch | 2012 | https://conductscience.org/library/papers/22767265 | PubMed |
| 20 | 38173302 | Diagnosis and management of neuroendocrine prostate cancer. | Prostate | 2024 | https://conductscience.org/library/papers/38173302 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| SYP | 6855 | PubTator's text mining | https://conductscience.org/library/genes/6855 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41547728
GET https://conductscience.org/api/papers/v1/41547728/references?page=2